Ipatasertib

Drug Profile

Ipatasertib

Alternative Names: GCD 0068; GDC-0068; RG-7440

Latest Information Update: 25 May 2017

Price : $50

At a glance

  • Originator Array BioPharma
  • Developer Chugai Pharmaceutical; Genentech
  • Class Antineoplastics; Heterocyclic bicyclo compounds; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Prostate cancer
  • Phase II Breast cancer; Gastrointestinal cancer
  • Phase I Solid tumours

Most Recent Events

  • 12 May 2017 Phase-III clinical trials in Prostate cancer (First-line therapy, Metastatic disease, Second-line therapy or greater, Hormone refractory) in USA (PO) (NCT03072238)
  • 09 Mar 2017 Hoffmann-La Roche plans a phase III trial for Prostate cancer (Metastatic disease, Combination therapy, First-line therapy, Hormone refractory) in USA, Australia, Austria, Belgium, Brazil, Canada, Costa Rica, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Japan, South Korea, Mexico, Norway, Poland, Portugal, Slovenia, Spain, Taiwan, Thailand and United Kingdom(NCT03072238)
  • 07 Oct 2016 Efficacy data from a phase I/II trial in Prostate cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top